-
Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure J. Hepatol. (IF 30.083) Pub Date : 2023-05-31 Banwari Agarwal, Rafael Bañares Cañizares, Faouzi Saliba, Maria Pilar Ballester, Dana Rodica Tomescu, Daniel Martin, Vanessa Stadlbauer, Gavin Wright, Mohammed Sheikh, Carrie Morgan, Carlos Alzola, Phillip Lavin, Daniel Green, Rahul Kumar, Sophie Caroline Sacleux, Gernot Schilcher, Sebastian Koball, Andrada Tudor, Jaak Minten, Gema Domenech, Rajiv Jalan
-
To the Editor: Germany – the potentially underestimated key player in European DCD type III organ donation? J. Hepatol. (IF 30.083) Pub Date : 2023-05-26 Janina Eden, Philipp Dutkowski, Andrea Schlegel
Abstract not available
-
Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis J. Hepatol. (IF 30.083) Pub Date : 2023-05-23 Fanny Lalloyer, Denis A. Mogilenko, Ann Verrijken, Joel T. Haas, Antonin Lamazière, Mostafa Kouach, Amandine Descat, Sandrine Caron, Emmanuelle Vallez, Bruno Derudas, Céline Gheeraert, Eric Baugé, Gaëtan Despres, Eveline Dirinck, Anne Tailleux, David Dombrowicz, Luc Van Gaal, Jerôme Eeckhoute, Philippe Lefebvre, Jean-François Goossens, Bart Staels
-
Reprogramming of rhythmic liver metabolism by intestinal clock J. Hepatol. (IF 30.083) Pub Date : 2023-05-23 Min Chen, Yanke Lin, Yongkang Dang, Yifei Xiao, Fugui Zhang, Guanghui Sun, Xuejun Jiang, Li Zhang, Jianhao Du, Shuyi Duan, Xiaojian Zhang, Zifei Qin, Jing Yang, Kaisheng Liu, Baojian Wu
-
Intestinal B-cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling J. Hepatol. (IF 30.083) Pub Date : 2023-05-22 Elena Kotsiliti, Valentina Leone, Svenja Schuehle, Olivier Govaere, Hai Li, Monika J. Wolf, Helena Horvatic, Sandra Bierwirth, Jana Hundertmark, Donato Inverso, Laimdota Zizmare, Avital Sarusi-Portuguez, Revant Gupta, Tracy O’Connor, Anastasios D. Giannou, Ahmad Mustafa Shiri, Yehuda Schlesinger, Maria Garcia Beccaria, Charlotte Rennert, Dominik Pfister, Mathias Heikenwalder
-
NIS2+™, an optimization of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: a prospective derivation and validation study J. Hepatol. (IF 30.083) Pub Date : 2023-05-22 Stephen A. Harrison, Vlad Ratziu, Jeremy Magnanensi, Yacine Hajji, Sylvie Deledicque, Zouher Majd, Christian Rosenquist, Dean Hum, Bart Staels, Quentin M. Anstee, Arun J. Sanyal
-
A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD J. Hepatol. (IF 30.083) Pub Date : 2023-05-22 ,
Abstract not available
-
Hepatic glucuronyl C5-epimerase combats obesity by stabilizing GDF15 J. Hepatol. (IF 30.083) Pub Date : 2023-05-20 Fei He, Haowen Jiang, Chang Peng, Tingting Wang, Rongrong Xiao, Meilin Chen, Nixue Song, Zhenyun Du, Hanlin Wang, Xiaoyu Ding, Yikai Shao, Jianping Fang, Yi Zang, Rong Hua, Jia Li, Kan Ding
-
Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions. J. Hepatol. (IF 30.083) Pub Date : 2023-05-18 Hamish Innes, Pierre Nahon
More than 50,000 people are diagnosed with hepatocellular carcinoma (HCC) every year in Europe. Many cases are known to specialist liver centres years before they present with HCC. Despite this, HCC is usually detected at a late stage, when prognosis is very poor. For more than two decades, clinical guidelines have recommended uniform surveillance for all cirrhosis patients. However, studies continue
-
-
Register now for the EASL Congress 2023, 21-24 June in Vienna (Austria)! J. Hepatol. (IF 30.083) Pub Date : 2023-05-17
Abstract not available
-
Register now for the EASL NAFLD Summit 2023, 21-23 September, in Prague (Czechia)! J. Hepatol. (IF 30.083) Pub Date : 2023-05-17
Abstract not available
-
Let’s unite Hepatology! Become an EASL member today and discover your benefits J. Hepatol. (IF 30.083) Pub Date : 2023-05-17
Abstract not available
-
EASL Studio is streaming live every week and bringing you hepatology news, from every angle J. Hepatol. (IF 30.083) Pub Date : 2023-05-17
Abstract not available
-
-
The changing world of liver transplantation J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Patrizia Burra
Abstract not available
-
Evaluation of recipients with significant comorbidity – Patients with cardiovascular disease J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Emmanuel A. Tsochatzis, Kymberly D. Watt, Lisa B. VanWagner, Elizabeth C. Verna, Annalisa Berzigotti
Liver transplant(ation) (LT) is the most effective treatment for patients with decompensated liver disease. The increasing prevalence of obesity and type 2 diabetes and the growing number of patients with non-alcoholic fatty liver disease being evaluated for LT, have resulted in a greater proportion of LT candidates presenting with a higher risk of cardiovascular disease. As cardiovascular disease
-
Liver transplantation in the patient with physical frailty J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Puneeta Tandon, Alberto Zanetto, Salvatore Piano, Julie K. Heimbach, Srinivasan Dasarathy
Frailty is a decline in functional reserve across multiple physiological systems. A key component of frailty is sarcopenia, which denotes a loss of skeletal muscle mass and impaired contractile function that ultimately result in physical frailty. Physical frailty/sarcopenia are frequent and contribute to adverse clinical outcomes before and after liver transplantation. Frailty indices, including the
-
Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation? J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Florent Artru, David Goldberg, Patrick S. Kamath
In this debate, the authors consider whether patients with acute-on-chronic liver failure grade 3 (ACLF-3) should receive higher liver transplant priority, with reference to the following clinical case: a 62-year-old male with a history of decompensated alcohol-associated cirrhosis, with recurrent ascites and hepatic encephalopathy, and metabolic comorbidities (type 2 diabetes mellitus, arterial hypertension
-
Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation? J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Arvinder Soin, Mickaël Lesurtel, Prashant Bhangui, Lorenzo Cocchi, Mohamed Bouattour, Pierre-Alain Clavien
In this debate, the authors consider whether patients with hepatocellular carcinoma (HCC) and portal vein tumour thrombosis are candidates for liver transplantation (LT). The argument for LT in this context is based on the premise that, following successful downstaging treatment, LT confers a much greater clinical benefit in terms of survival outcomes than the available alternative (palliative systemic
-
Early liver transplantation for severe acute alcohol-related hepatitis after more than a decade of experience J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Giacomo Germani, Philippe Mathurin, Michael R. Lucey, James Trotter
In patients with severe acute alcohol-related hepatitis not responding to medical therapy, early liver transplantation (LT) represents the only effective therapy and, when performed within strict and well-defined protocols, it is associated with a clear survival benefit and acceptable rates of return to alcohol use after transplantation. However, there is still high variability in access to LT for
-
Transplantation for metastatic liver disease J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Ashley Kieran Clift, Morten Hagness, Kuno Lehmann, Charles B. Rosen, Rene Adam, Vincenzo Mazzaferro, Andrea Frilling
The liver is a common site of metastases from many cancers, particularly those originating in the gastrointestinal tract. Liver transplantation is an uncommonly used but promising and at times controversial treatment option for neuroendocrine and colorectal liver metastases. Transplantation with meticulous patient selection has been associated with excellent long-term outcomes in individuals with neuroendocrine
-
Evaluation of living donors for hereditary liver disease (siblings, heterozygotes) J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Mureo Kasahara, Johnny C. Hong, Anil Dhawan
Living donor liver transplantation (LDLT) is recognised as an alternative treatment modality to reduce waiting list mortality and expand the donor pool. Over recent decades, there have been an increasing number of reports on the use of LT and specifically LDLT for familial hereditary liver diseases. There are marginal indications and contraindications that should be considered for a living donor in
-
Issues in multi-organ transplantation of the liver with kidney or heart in polycystic liver-kidney disease or congenital heart disease: Current practices and immunological aspects J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Timucin Taner, Moira B. Hilscher, Christopher R. Broda, Joost P.H. Drenth
Solid organ transplantation has become an integral part of the management of patients with end-stage diseases of the kidney, liver, heart and lungs. Most procedures occur in isolation, but multi-organ transplantation of the liver with either the kidney or heart has become an option. As more patients with congenital heart disease and cardiac cirrhosis survive into adulthood, particularly after the Fontan
-
Donation after circulatory death: Novel strategies to improve the liver transplant outcome J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Riccardo De Carlis, , Burcin Taner
In many countries, donation after circulatory death (DCD) liver grafts are used to overcome organ shortages; however, DCD grafts have been associated with an increased risk of complications and even graft loss after liver transplantation. The increased risk of complications is thought to correlate with prolonged functional donor warm ischaemia time. Stringent donor selection criteria and utilisation
-
Machine perfusion of the liver and bioengineering J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Andrea Schlegel, Hynek Mergental, Constantino Fondevila, Robert J. Porte, Peter J. Friend, Philipp Dutkowski
With the increasing number of accepted candidates on waiting lists worldwide, there is an urgent need to expand the number and the quality of donor livers. Dynamic preservation approaches have demonstrated various benefits, including improving liver function and graft survival, and reducing liver injury and post-transplant complications. Consequently, organ perfusion techniques are being used in clinical
-
Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Aldo J. Montano-Loza, Manuel L. Rodríguez-Perálvarez, George-Philippe Pageaux, Alberto Sanchez-Fueyo, Sandy Feng
Outcomes after liver transplantation have continuously improved over the past decades, but long-term survival rates are still lower than in the general population. The liver has distinct immunological functions linked to its unique anatomical configuration and to its harbouring of a large number of cells with fundamental immunological roles. The transplanted liver can modulate the immunological system
-
Artificial intelligence, machine learning, and deep learning in liver transplantation J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Mamatha Bhat, Madhumitha Rabindranath, Beatriz Sordi Chara, Douglas A. Simonetto
Liver transplantation (LT) is a life-saving treatment for individuals with end-stage liver disease. The management of LT recipients is complex, predominantly because of the need to consider demographic, clinical, laboratory, pathology, imaging, and omics data in the development of an appropriate treatment plan. Current methods to collate clinical information are susceptible to some degree of subjectivity;
-
Post-liver transplantation patient experience J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Alyson Kaplan, Marko Korenjak, Robert S. Brown
Given improvements in post-transplant patient and graft survival, there is a growing need to focus on patient experience and health-related quality of life (HRQOL). Though liver transplantation can be life-saving, it can also be associated with significant morbidity and complications. Patient HRQOL improves after transplantation, but it may not improve to that of age-matched cohorts. Understanding
-
Mini-Review for Journal of HepatologyTherapeutic opportunities for the treatment of NASH with genetically validated targets J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Daniel Lindén, Stefano Romeo
The identification of genetic variants associated with fatty liver disease (FLD) from genome wide association studies (GWASs) started in 2008 when single nucleotide polymorphisms in PNPLA3, the gene encoding patatin-like phospholipase domain-containing 3, were found to be associated with altered hepatic fat content. Since then, several genetic variants associated with protection from or increased risk
-
Hilpda, A New Player In Nash-Driven Hcc, Links Hypoxia Signaling With Ceramide Synthesis J. Hepatol. (IF 30.083) Pub Date : 2023-05-17 Jose C. Fernandez-Checa, Sandra Torres, Carmen Garcia-Ruiz
Abstract not available
-
Reply to Correction for length bias reduces the mortality benefit from HCC surveillance J. Hepatol. (IF 30.083) Pub Date : 2023-05-16 Amit G. Singal, Jorge Marrero, Neehar D. Parikh
Abstract not available
-
RSK2 inactivation cooperates with AXIN1 inactivation or ß-catenin activation to promote hepatocarcinogenesis J. Hepatol. (IF 30.083) Pub Date : 2023-05-16 Samantha Schaeffer, Barkha Gupta, Anna-Line Calatayud, Julien Calderaro, Stefano Caruso, Théo Z. Hirsch, Laura Pelletier, Jessica Zucman-Rossi, Sandra Rebouissou
-
Immunobiology of Cholangiocarcinoma J. Hepatol. (IF 30.083) Pub Date : 2023-05-16 Jennifer L. Tomlinson, Juan W. Valle, Sumera I. Ilyas
Recent literature has significantly advanced our knowledge and understanding of the cholangiocarcinoma tumor immune microenvironment. Detailed characterization of the immune landscape has defined new patient subtypes. While not utilized in clinical practice yet, these novel classifications will help inform decisions regarding immunotherapeutic approaches. Suppressive immune cells, such as tumor-associated
-
Painless jaundice with segmental obstructive cholestasis J. Hepatol. (IF 30.083) Pub Date : 2023-05-15 Felix Bolduan, Dominik Geisel, Stefan Pahl, Alexander Wree, Frank Tacke
Abstract not available
-
Ammonia – an enduring foe – What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy J. Hepatol. (IF 30.083) Pub Date : 2023-05-12 Debbie L. Shawcross, Dominique Thabut, Piero Amodio
Abstract not available
-
The influence of invasive procedures on acute HBV and HCV infections J. Hepatol. (IF 30.083) Pub Date : 2023-05-10 Huan Deng, Yisheng Pan
Abstract not available
-
Changing epidemiology, global trends and implications for outcomes of NAFLD J. Hepatol. (IF 30.083) Pub Date : 2023-05-09 Vincent Wai-Sun Wong, Mattias Ekstedt, Grace Lai-Hung Wong, Hannes Hagström
Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common liver disease globally, currently estimated to affect 38% of the global population. A minority of patients with NAFLD will progress to cirrhosis or hepatocellular carcinoma, but the total number of this vast population that risk such severe outcomes is increasing. Worryingly, persons are affected by NAFLD at an earlier age
-
Nomenclature, Diagnosis and Management of Drug-induced Autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report J. Hepatol. (IF 30.083) Pub Date : 2023-05-08 Raúl J. Andrade, Guruprasad P. Aithal, Ynto S. de Boer, Rodrigo Liberal, Alexander Gerbes, Arie Regev, Benedetta Terziroli Beretta-Piccoli, Christoph Schramm, David E. Kleiner, Eleonora De Martin, Gerd A. Kullak-Ublick, Guido Stirnimann, Harshad Devarbhavi, John M. Vierling, Michael P. Manns, Marcial Sebode, Maria Carlota Londoño, Mark Avigan, Mercedes Robles-Diaz, Miren García-Cortes, Elena Gómez
Drug-induced liver injury (DILI) can mimic almost all other liver disorders. A phenotype increasingly ascribed to drugs is autoimmune-like hepatitis (ALH). This article summarizes the major topics discussed at a joint International Conference held between Drug-Induced Liver Injury consortium and the International Autoimmune Hepatitis Group. DI-ALH is a liver injury with laboratory and/or histological
-
Defining severe NAFLD based on ICD codes in large cohorts: balancing feasibility and limitations J. Hepatol. (IF 30.083) Pub Date : 2023-05-07 Lu Long, Xiaorui Zhou
Abstract not available
-
To the Editor: Risk stratification and outcome assessment in randomized controlled trials with machine perfusion J. Hepatol. (IF 30.083) Pub Date : 2023-05-06 Janina Eden, Stefanie von Felten, Philipp Dutkowski, Andrea Schlegel
Abstract not available
-
Caveats to link in vitro mechanistic mitophagy studies to the pathogenesis of non-alcoholic steatohepatitis J. Hepatol. (IF 30.083) Pub Date : 2023-05-06 Chen Zhang, Wen-Xing Ding
Abstract not available
-
Global incidence of NAFLD: Sets alarm bells ringing about NAFLD in China again J. Hepatol. (IF 30.083) Pub Date : 2023-05-04 Lu Li, Zeyu Wang, Yong Jiang
In recent years, the rapid rise in the incidence of non-alcoholic fatty liver disease (NAFLD) in China has become a pressing issue, arousing particular concern among the public. And we noticed a recent meta-analysis published in your esteemed journal and read it with great interest. We have identified some issues that we believe warrants further attention, which may offer some useful guidance in comprehensively
-
Fingolimod, a sphingosine-1-phosphate agonist for the treatment of hepatopulmonary syndrome: Queries and concerns J. Hepatol. (IF 30.083) Pub Date : 2023-05-03 Muhammad Uwais Ashraf, Arka De, Sweta Rose
Abstract not available
-
TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis J. Hepatol. (IF 30.083) Pub Date : 2023-05-02 Hélène Larrue, Gennaro D’Amico, Pol Olivas, Yong Lv, Theresa Bucsics, Marika Rudler, Tilman Sauerbruch, Virginia Hernandez-Gea, Guohong Han, Thomas Reiberger, Dominique Thabut, Jean-Pierre Vinel, Jean-Marie Péron, Juan-Carlos Garcia-Pagan, Christophe Bureau
-
Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation J. Hepatol. (IF 30.083) Pub Date : 2023-04-29 Ombretta Colasanti, Rani Burm, Hao-En Huang, Tobias Riedl, Jannik Traut, Nadine Gillich, Teng-Feng Li, Laura Corneillie, Suzanne Faure-Dupuy, Oliver Grünvogel, Danijela Heide, Ji-Young Lee, Cong Si Tran, Uta Merle, Maria Chironna, Florian F.W. Vondran, Katharina Esser-Nobis, Marco Binder, Ralf Bartenschlager, Mathias Heikenwälder, Volker Lohmann
-
An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography J. Hepatol. (IF 30.083) Pub Date : 2023-04-29 Jia-xu Liang, Javier Ampuero, Hao Niu, Kento Imajo, Mazen Noureddin, Jaideep Behari, Dae Ho Lee, Richard L. Ehman, Fredrik Rorsman, Johan Vessby, Juan R. Lacalle, Ferenc E. Mózes, Michael Pavlides, Quentin M. Anstee, Stephen A. Harrison, Javier Castell, Rohit Loomba, Manuel Romero-Gómez
-
Kratom Induced Acute Liver Injury: A Case Study and the Importance of Herbal Supplement Regulation J. Hepatol. (IF 30.083) Pub Date : 2023-04-28 Katerina Roma, Salman Mohammed, Blake Sieck, Katrina Naik, Shahid Wahid
Abstract not available
-
Hospital HCV elimination in addition to universal precautions could reduce incidence and infection burden in Italy J. Hepatol. (IF 30.083) Pub Date : 2023-04-28 Loreta A. Kondili, Maria Grazia Rumi, Antonio Craxi
Abstract not available
-
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta J. Hepatol. (IF 30.083) Pub Date : 2023-04-27 Julius Hollnberger, Yang Liu, Simin Xu, Silvia Chang, Ross Martin, Savrina Manhas, Thomas Aeschbacher, Bin Han, Tahmineh Yazdi, Lindsey May, Dong Han, Alex Shornikov, John Flaherty, Dmitry Manuilov, Vithika Suri, Tarik Asselah, Pietro Lampertico, Heiner Wedemeyer, Soo Aleman, Christopher Richards, Stephan Urban
-
Neurological worsening in Wilson Disease – Clinical classification and outcome J. Hepatol. (IF 30.083) Pub Date : 2023-04-26 Isabelle Mohr, Jan Pfeiffenberger, Ecem Eker, Uta Merle, Aurélia Poujois, Aftab Ala, Karl Heinz Weiss
-
Bio-molecular map of albumin identifies signatures of severity and early mortality in Acute Liver Failure J. Hepatol. (IF 30.083) Pub Date : 2023-04-26 Neha Sharma, Sushmita Pandey, Manisha Yadav, Babu Mathew, Vasundhra Bindal, Nupur Sharma, Gaurav Tripathi, Sadam H. Bhat, Abhishak Gupta, , Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras
-
A ‘one-stop-shop’ point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study J. Hepatol. (IF 30.083) Pub Date : 2023-04-26 Yumi Sheehan, Evan B. Cunningham, Amanda Cochrane, Marianne Byrne, Tracey Brown, Colette McGrath, Lise Lafferty, Nicodemus Tedla, Gregory J. Dore, Andrew R. Lloyd, Jason Grebely
-
A randomized controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C J. Hepatol. (IF 30.083) Pub Date : 2023-04-23 Mohamed El-Kassas, Mohammed Emadeldeen, Mohamed Hassany, Gamal Esmat, Ahmed Ali Gomaa, Fathiya El-Raey, Stephen E. Congly, Hongqun Liu, Samuel S. Lee
-
Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming J. Hepatol. (IF 30.083) Pub Date : 2023-04-23 Beatriz Aguilar-Bravo, Silvia Ariño, Delia Blaya, Elisa Pose, Raquel A. Martinez García de la Torre, María U. Latasa, Celia Martínez-Sánchez, Laura Zanatto, Laura Sererols-Viñas, Paula Cantallops-Vilà, Silvia Affo, Mar Coll, Xavier Thillen, Laurent Dubuquoy, Matías A. Avila, Josepmaria Argemi, Arantza Lamas Paz, Yulia A. Nevzorova, Francisco Javier Cubero, Ramon Bataller, Pau Sancho-Bru
-
A randomized-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock J. Hepatol. (IF 30.083) Pub Date : 2023-04-23 Rakhi Maiwall, Samba Siva Rao Pasupuleti, Ashini Kumar Hidam, Anupam Kumar, Harsh Vardhan Tevethia, Rajan Vijayaraghavan, Arpita Majumdar, Adarsh Prasher, Sherin Thomas, Rajendra Prasad Mathur, Guresh Kumar, Shiv Kumar Sarin
-
The role of ETV4 in HCC: How transcription factors can inform immunotherapy combination treatments J. Hepatol. (IF 30.083) Pub Date : 2023-04-23 Amanda J. Craig, Maruhen A.D. Silveira
Abstract not available
-
Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease J. Hepatol. (IF 30.083) Pub Date : 2023-04-21 Tim Meyer, Sevasti Galani, Andre Lopes, Arndt Vogel
Abstract not available
-
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease J. Hepatol. (IF 30.083) Pub Date : 2023-04-21 Maria Kjaergaard, Katrine Prier Lindvig, Katrine Holtz Thorhauge, Peter Andersen, Johanne Kragh Hansen, Nanna Kastrup, Jane Møller Jensen, Camilla Dalby Hansen, Stine Johansen, Mads Israelsen, Nikolaj Torp, Morten Beck Trelle, Shan Shan, Sönke Detlefsen, Steen Antonsen, Jørgen Ellegaard Andersen, Isabel Graupera, Pere Ginés, Maja Thiele, Aleksander Krag
-
Unraveling the role of the liver myeloid compartment during hepatitis C virus cure J. Hepatol. (IF 30.083) Pub Date : 2023-04-21 Emilie Crouchet, Thomas F. Baumert
Abstract not available